Skip to main content
lexblog.com/lib/AWH04Z15viewrecordjson
{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Vision Loss Associated With Ozempic, Mounjaro, And Other GLP-1 Drugs",
    "url": "https://www.lexblog.com/2026/10/16/vision-loss-associated-with-ozempic-mounjaro-and-other-glp-1-drugs/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-AWH04Z15",
        "url": "https://www.lexblog.com/lib/AWH04Z15/"
    },
    "datePublished": "2026-10-16T20:01:54-04:00",
    "dateModified": "2026-10-16T20:01:54-04:00",
    "author": {
        "@type": "Person",
        "name": "Tom Lamb"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Law Offices of Thomas J. Lamb, P.A."
    },
    "organizationScope": "at-publication",
    "isPartOf": "Drug Injury Watch",
    "about": "Class Action & Mass Torts · Food, Drug & Agriculture · Personal Injury",
    "sourceUrl": "https://drug-injury.com/2026/10/16/vision-loss-associated-with-ozempic-mounjaro/",
    "sourceStability": "may-move"
}